Hydrocelectomy
Hydrocelectomy explained: honest success and recurrence rates compared with aspiration, recovery, and risks — with sources, not guesswork.
Also known as: hydrocele surgery, hydrocele repair
✓ Clinician-reviewed information- Hydrocelectomy is the surgical removal or repair of a hydrocele — a fluid collection around the testicle — and is widely considered the definitive, gold-standard treatment for hydroceles needing active management.
- Published success (cure) rates are consistently high, commonly 84–95%, with recurrence as low as 1.3–7% in most modern series.
- This compares favourably with aspiration and sclerotherapy, which is cheaper and less invasive but shows meaningfully higher recurrence — some studies report over a third of sclerotherapy patients.
- Hydrocelectomy does carry a higher immediate complication rate than sclerotherapy in several comparative studies — an honest trade-off, not a simple "surgery is better in every respect".
- Not every hydrocele needs treatment — small, symptom-free hydroceles are often simply monitored, and this procedure is for cases causing genuine bother or complication.
About hydrocelectomy
A hydrocele is a build-up of fluid in the thin sac around the testicle, causing painless scrotal swelling. Hydrocelectomy is the surgery to treat it. The surgeon opens the fluid-filled sac, drains it, and then either removes the excess sac tissue or folds and stitches it back on itself so it can no longer collect fluid. It is done through a small cut, usually in the scrotum, under general, spinal, or sometimes local anaesthesia.
It is consistently described as the gold-standard treatment for hydroceles that need active management, and the data supports this. Across studies, hydrocelectomy achieves cure rates commonly between 84% and 95%, with recurrence as low as 1.3% to 7% in most recent series. One study found near-identical recurrence between two surgical approaches, and a cost-and-outcome comparison found 94.8% success for surgery versus 92.8% for sclerotherapy — both can work well, but surgery generally offers more consistent, durable results.
The main alternative, aspiration and sclerotherapy, draws the fluid out with a needle and injects an irritant to close the space. It is genuinely useful and much less invasive, but the evidence consistently shows it is less durable. One study found 76% success for sclerotherapy versus 84% for surgery, and others report much higher recurrence after sclerotherapy — one cohort found 38.9% recurrence after initial sclerotherapy. It is not that sclerotherapy is ineffective; for many men it works well. But the honest pattern is that surgery is the more durable, one-time fix for most patients.
That durability comes at a cost, and it deserves equally honest treatment. Several studies found hydrocelectomy carries a higher immediate complication rate than sclerotherapy — one older but still-cited trial found post-operative fever in 26.7% of surgery patients (versus 6.7%) and infection in 14% (versus none), with more lost work days and higher cost. Modern, minimally invasive surgical technique reports far lower complication rates — one trial found 12.88% versus 37% for a conventional approach — so, much like varicocelectomy, technique genuinely matters.
Taken together: hydrocelectomy is the more definitive, durable treatment, generally recommended for larger, more bothersome, or recurrent hydroceles and for younger, otherwise healthy men who want a one-time solution. Aspiration and sclerotherapy remains a reasonable, less invasive, lower-immediate-risk alternative — particularly for older men or men with significant other health conditions — but with a clearly higher chance of the hydrocele returning. This is a genuine choice to discuss honestly with your specialist, not a case of one option being simply superior.
The honest, consistent pattern across the literature is that surgery offers a meaningfully more durable, one-time fix for most patients, at the cost of being more invasive and more expensive.
Who it is for
- •Men with a symptomatic, bothersome, or cosmetically distressing hydrocele that has not resolved on its own
- •Men with a large hydrocele causing physical discomfort or practical difficulty
- •Younger, otherwise healthy men who want a definitive, one-time treatment with the lowest long-term recurrence risk
- •Men who have had recurrence after previous aspiration and sclerotherapy
- •Older men or men with significant medical comorbidities where surgical and anaesthetic risk is a more prominent consideration (often better suited to sclerotherapy)
- •Men who prioritise a lower-cost, less invasive first option and are willing to accept a higher chance of needing repeat treatment
- •Men with a small, symptom-free hydrocele, which is often simply monitored rather than treated
Preparing for surgery
What recovery looks like
Risks and complications
Common questions
Is surgery really better than aspiration and sclerotherapy?
How likely is my hydrocele to come back after surgery?
Why would anyone choose sclerotherapy if surgery works better long-term?
How much does surgical technique matter for complication rates?
Is hydrocelectomy painful?
Will surgery affect my fertility?
Do I need a scrotal ultrasound before surgery even though I was diagnosed by examination?
Can a hydrocele recur years after apparently successful surgery?
Patient reviews
Been treated? Your honest review of Hydrocelectomy helps the next patient.
Be the first to share your experience of this procedure. We read and verify every review before it is published.
Write the first reviewSources
- Comparison of outcomes and costs of surgery versus sclerotherapy to treat hydrocele. https://pmc.ncbi.nlm.nih.gov/articles/PMC8277233/
- Comparison of aspiration-sclerotherapy with hydrocelectomy in the management of hydrocele: a prospective randomized study. https://www.sciencedirect.com/science/article/pii/S1743919109000958
- Minimally access versus conventional hydrocelectomy: a randomized trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC4757005/
- Sclerotherapy in the Treatment of Hydroceles: A Comprehensive Review. 2024. https://journals.sagepub.com/doi/10.1177/08465371241243271
